Rebecca M O'Brien

US Patent:

8431386, Apr 30, 2013

Filed:

Sep 7, 2012

Appl. No.:

13/606299

Inventors:

Randice Lisa Altschul - Cliffside Park NJ, US
Myron Rapkin - Indianapolis IN, US
Rebecca O'Brien - Shell Knob MO, US

Assignee:

Pop Test LLC - Cliffside Park NJ

International Classification:

C12M 1/34

US Classification:

4352871, 4352877, 4352887

Abstract:

A device is disclosed for conducting a non-invasive analysis of a bodily fluid to determine the presence and level of a certain constituent carried by the bodily fluid. An indicator formulation of the device changes color in response to exposure to the constituent to provide a visible indication of the presence and level of the constituent carried by the bodily fluid. A carrier substrate of the device is constructed of a material having voids providing a high void volume within the substrate. The device is made by applying a chromagen to the carrier substrate to create a chromagen-laden carrier member. Then, a selected reagent having a particular constituent-specific formulation is applied to the chromagen-laden member. The selected reagent then combines with the chromagen, thereby establishing the indicator formulation within the carrier substrate in place for reception of a sample of the bodily fluid.

US Patent:

20120100563, Apr 26, 2012

Filed:

Oct 21, 2011

Appl. No.:

13/278306

Inventors:

Randice Lisa Altschul - Cliffside Park NJ, US
Myron Rapkin - Indianapolis IN, US
Rebecca O'Brien - Shell Knob MO, US

Assignee:

POP TEST LLC - Cliffside Park NJ

International Classification:

C12Q 1/28
C12Q 1/60
C12Q 1/62
C12Q 1/54

US Classification:

435 10, 435 14, 435 11, 435 28

Abstract:

A device is disclosed for conducting a non-invasive analysis of a bodily fluid to determine the presence and level of a certain constituent carried by the bodily fluid. An indicator formulation of the device changes color in response to exposure to the constituent to provide a visible indication of the presence and level of the constituent carried by the bodily fluid. A carrier substrate of the device is constructed of a material having voids providing a high void volume within the substrate.The device is made by applying a chromagen to the carrier substrate to create a chromagen-laden carrier member. Then, a selected reagent having a particular constituent-specific formulation is applied to the chromagen-laden member. The selected reagent then combines with the chromagen, thereby establishing the indicator formulation within the carrier substrate in place for reception of a sample of the bodily fluid.

US Patent:

20120201747, Aug 9, 2012

Filed:

Feb 2, 2012

Appl. No.:

13/364651

Inventors:

Randice Lisa Altschul - Cliffside Park NJ, US
Neil David Theise - New York NY, US
Myron Rapkin - Indianapolis IN, US
Rebecca O'Brien - Shell Knob MO, US

Assignee:

POP TEST CORTISOL LLC - Cliffside Park NJ

International Classification:

A61K 31/58
A61K 51/00
A61K 31/7068
A61K 33/24
A61K 31/665
A61K 31/7076
A61K 38/12
A61K 31/704
A61K 38/50
A61P 25/24
A61P 25/18
A61P 5/00
A61P 35/02
C07J 17/00
G01N 33/566
G01N 33/53
C40B 30/04
A61N 5/00
A61J 1/05
A61P 35/00
B82Y 5/00

US Classification:

424 111, 514174, 514171, 514 49, 424649, 514110, 514 48, 514 192, 514 34, 514170, 424 946, 540116, 436501, 435 79, 506 9, 422430, 600 1, 604403, 977773, 977915

Abstract:

This invention relates to a low cost rapid response diagnostic system to determine cortisol levels in patients selected as potential candidates for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist, such as ORG 34517. The rapid, sensitive, and inexpensive test can be used to determine patients who have non-normal cortisol production or disordered circadian rhythms as a method for selecting subjects for GCR antagonist therapy for whom it is likely to have beneficial and/or therapeutic effects, and can also be used to monitor changes in cortisol levels in response to treatment.

US Patent:

20120245552, Sep 27, 2012

Filed:

Mar 21, 2012

Appl. No.:

13/425964

Inventors:

Randice Lisa Altschul - Cliffside Park NJ, US
Neil David Theise - New York NY, US
Myron Rapkin - Indianapolis IN, US
Rebecca O'Brien - Shell Knob MO, US

Assignee:

POP TEST CORTISOL LLC - Cliffside Park NJ

International Classification:

A61J 1/05
A61P 29/00
A61P 19/00
A61P 19/04
A61P 21/00
A61P 1/00
A61P 1/18
A61P 7/00
A61P 9/00
A61P 5/00
A61P 13/00
A61P 13/12
A61P 13/10
A61P 25/00
A61P 27/00
A61J 1/00
A61K 31/573

US Classification:

604403, 514171, 206438, 206570

Abstract:

This invention relates to compositions and methods for treating GC-responsive conditions and for reducing and preventing side-effects of GC treatment in patients.

US Patent:

20120253312, Oct 4, 2012

Filed:

Mar 28, 2012

Appl. No.:

13/432174

Inventors:

Randice Lisa Altschul - Cliffside Park NJ, US
Neil David Theise - New York NY, US
Myron Rapkin - Indianapolis IN, US
Rebecca O'Brien - Shell Knob MO, US

Assignee:

POP TEST CORTISOL LLC - Cliffside Park NJ

International Classification:

A61J 1/14
A61P 31/00
A61J 1/00
A61K 31/56

US Classification:

604403, 514182, 206570

Abstract:

The invention relates to compounds and methods for the prevention and/or treatment of infection after stroke.

US Patent:

20120263660, Oct 18, 2012

Filed:

Apr 16, 2012

Appl. No.:

13/447345

Inventors:

Randice Lisa Altschul - Cliffside Park NJ, US
Neil David Theise - New York NY, US
Myron Rapkin - Indianapolis IN, US
Rebecca O'Brien - Shell Knob MO, US

Assignee:

POP TEST CORTISOL LLC - Cliffside Park NJ

International Classification:

A61K 31/58
A61Q 1/12
A61Q 19/04
A61Q 3/02
A61Q 9/02
A61Q 5/06
A61Q 5/02
A61Q 5/12
A61Q 19/10
A61Q 17/04
A61Q 5/04
A61Q 15/00
A61Q 19/00
A61K 8/67
A61K 8/66
A61K 8/92
A61P 31/00
A61P 17/10
A61Q 19/02
A61P 17/14
A61P 17/00
A61Q 5/10
A61Q 9/04
A61K 38/43
A61K 36/886
A61K 8/97
A61K 31/704
B65D 69/00
A61K 8/63

US Classification:

424 59, 514172, 424 69, 424 61, 424 65, 424 62, 514174, 8405, 424 941, 424 63, 424744, 514 33, 206570

Abstract:

This invention relates to the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the prevention or treatment of stress induced hair loss.

US Patent:

20120282636, Nov 8, 2012

Filed:

May 4, 2012

Appl. No.:

13/463956

Inventors:

Randice Lisa Altschul - Cliffside Park NJ, US
Neil David Theise - New York NY, US
Myron Rapkin - Indianapolis IN, US
Rebecca O'Brien - Shell Knob MO, US

Assignee:

POP TEST, LLC - Cliffside Park NJ

International Classification:

C12M 1/42
G01N 21/76
G01N 33/558

US Classification:

435 792, 4352872, 4352878, 436501, 422 69, 422 52

Abstract:

The invention provides for rapid response analysis through lateral flow chromatographic assays of specific antigens present in human or animal fluids, or in agricultural, microbial or biological products, with an audio and visual result of the analysis and when needed, an electronic surge to provide heat for rapid results. A lateral flow device for conducting the analysis includes a plurality of components, and a method for making the device forms components of the device on an elongate, ribbon-like substrate of dielectric material, then folds the substrate into shorter lengths which are then secured together to establish a multiple-layered, self-sustaining structure.

US Patent:

20130203094, Aug 8, 2013

Filed:

Mar 15, 2013

Appl. No.:

13/836679

Inventors:

POP TEST LLC - Cliffside Park NJ, US
Myron Rapkin - Indianapolis IN, US
Rebecca O'Brien - Shell Knob MO, US

Assignee:

POP TEST LLC - Cliffside Park NJ

International Classification:

G01N 21/78

US Classification:

435 14, 4352887, 435 25

Abstract:

A device and method are disclosed for use in the conduct of a non-invasive analysis of a bodily fluid to determine the presence and level of a certain constituent carried by the bodily fluid, which analysis utilizes an indicator formulation that changes color in response to exposure to the constituent to provide a visible indication of the presence and level of the constituent carried by the bodily fluid. A stabilizing formulation is carried in a vessel for mixing with a sample of the bodily fluid to be analyzed. The stabilizing formulation includes a first component for promoting formation of a film, a second component for adjusting the pH of the sample and inhibiting microbial digestion of the certain constituent carried by the bodily fluid, and a third component for reducing interference of ascorbic acid present in the bodily fluid. Where the certain constituent is glucose, the stabilizing formulation includes a microbial digestion inhibitor.